Global CAR-T Cell Therapy Treatment Market is Growing with 30.0% in the Forecast Period of 2021 to 2028

The CAR-T Cell Therapy Treatment Industry will relinquish an approximated estimate at a frequency of 30.0% for the projection space of 2021 to 2028 with factor such as increase in usage of CAR-T cell therapy for the treatment of cancer and infectious diseases and rise in awareness about immunotherapies. Increasing prevalence of cancer also acts as a major factor for the growth of the CAR-T cell therapy treatment market. Adoption of CAR-T cell therapies in emerging markets and increase in investment for research and development have also given a boom to the global CAR-T cell therapy treatment market.

The presence of pipeline therapies has propelled the demand of the CAR-T cell therapy treatment market. However, adverse side effects of therapies and high cost associated with therapies has decreased the demand of the CAR-T cell therapy treatment market.  

CAR-T Cell Therapy Treatment Market Scenario                        

According to Data Bridge Market Research, the market for CAR-T cell therapy treatment in North America has the highest market share followed by Europe and Asia-Pacific. Market leader is Kite Pharma (a subsidiary of Gilead Sciences, Inc.) which accounts an estimated market share of approximately 53% to 57% globally. The company has gained outstanding sales by providing novel CAR-T cell therapy treatment.

  • In December 2017, Kite Pharma (a subsidiary of Gilead Sciences, Inc.) had acquired the Cell Design Labs in order to enhance their footprint in CAR-T cell therapy treatment and other different cell therapies market. Cell Design Labs is highly focused on the research and development of the immunotherapies which is used for the treatment of cancer. This acquisition has helped the company to enhance their R&D platform with new and innovative technologies.

CAR-T Cell Therapy Treatment Market

Trends Impacting the CAR-T Cell Therapy Treatment Market

Now the question is which other regions Kite Pharma (a subsidiary of Gilead Sciences, Inc.) and Novartis AG are targeting? Data Bridge Market Research has forecasted a large growth in North America CAR-T cell therapy treatment market and the market leaders targeting the U.S. and Canada to be their next revenue pockets for 2021.

The global CAR-T cell therapy treatment market is becoming more competitive with companies such as Kite Pharma (a subsidiary of Gilead Sciences, Inc.) and Novartis AG. These are the top dominating companies in CAR-T cell therapy treatment market and have launched novel CAR-T cell therapy treatment in the market. The Data Bridge Market Research new reports highlight the major growth factors and opportunities in the global CAR-T cell therapy treatment market.

For more analysis on the global CAR-T cell therapy treatment market, request for a briefing with our analysts https://www.databridgemarketresearch.com/speak-to-analyst/?dbmr=global-car-t-cell-therapy-treatment-market

New CAR-T Cell Therapy Treatment Market Development

  • In February 2021, Novartis AG had received the approval from Therapeutic Goods Administration for manufacturing and supplying of the CAR-T cell therapies in Australia. The Peter MacCallum Cancer Center in Melbourne considered as the first approved manufacturing site of immunotherapies among others in Australia which are applicable for the treatment of cancer patients. This expansion helped the company to boost up its oncology business globally especially the innovative CAR-T cell therapies which has ultimately boosted the overall sales of the product.

Scope of the Global CAR-T Cell Therapy Treatment market

Global CAR-T cell therapy treatment market is segmented on the basis of countries into the U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Belgium, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, rest of Europe, Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, Vietnam, rest of Asia-Pacific, Brazil, Argentina, Peru, rest of South America, Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt  and rest of Middle East and Africa.

  • All country based analysis of the global CAR-T cell therapy treatment market is further analyzed based on maximum granularity into further segmentation. On the basis of product, the CAR-T cell therapy treatment market is segmented into autologous CAR-T cells and allogeneic CAR-T cells. On the basis of structure, the CAR-T cell therapy treatment market is segmented into first generation CAR-T cells, second generation CAR-T cells, third generation CAR-T cells and fourth generation CAR-T cells. On the basis of targeted antigens, the CAR-T cell therapy treatment market is segmented into antigens on solid tumors, antigens on hematologic malignancies and others. On the basis of brand, the CAR-T cell therapy treatment market is segmented into yescarta, kymriah, tecartus and others. On the basis of therapeutic application, the CAR-T cell therapy treatment market is segmented into hematological malignancies, pancreatic cancer, breast cancer, lung cancer, gastric cancer, multiple myeloma, chronic lymphocytic leukemia, mantle cell lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, acute lymphoblastic leukemia and others. On the basis of end user, the CAR-T cell therapy treatment market is segmented into hospitals, specialty clinics and others. On the basis of distribution channel, the CAR-T cell therapy treatment market is segmented into hospitals pharmacy and others.

To know more about the study https://www.databridgemarketresearch.com/reports/global-car-t-cell-therapy-treatment-market

Key Pointers Covered in Global CAR-T Cell Therapy Treatment Market Industry Trends and Forecast to 2028

  • Market Size
  • Top to Bottom Market Analysis
  • Recent Developments for Market Competitors
  • Recent Market Value for Different Countries
  • Market Value and Over View of CAR-T Cell Therapy Treatment
  • Company Profiling of Top Eight Players of CAR-T Cell Therapy Treatment

Key Market Competitors Covered in the Report

  • Autolus
  • Atara Biotherapeutics, Inc.
  • Amgen Inc.
  • Bellicum Phamaceuticals, Inc.
  • bluebird bio, inc.,
  • Adaptimmune Therapeutics plc
  • Bristol-Myers Squibb Company
  • Xyphos (a subsidiary of Astellas Pharma Inc.)
  • Johnson & Johnson Services, Inc.
  • BioAtla Inc.
  • AbbVie Inc.
  • Novartis AG
  • Kite Pharma (a subsidiary of Gilead Sciences, Inc.)
  • Aurora Biopharma
  • Tmunity Therapeutics
  • Cartherics Pty ltd
  • CARINA BIOTECH
  • Ziopharm Oncology, Inc.
  • Cellectis SA
  • Mustang Bio
  • Sorrento Therapeutics, Inc.
  • Cartesian Therapeutics, Inc.
  • TC BioPharm Limited
  • Celyad Oncology SA
  • Tessa Therapeutics Ltd.

Above are the key players covered in the report, to know about more and exhaustive list of CAR-T cell therapy treatment companies’, contact us https://www.databridgemarketresearch.com/toc/?dbmr=global-car-t-cell-therapy-treatment-market

Research Methodology: Global CAR-T Cell Therapy Treatment Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your enquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include vendor positioning grid, market time line analysis, market overview and guide, company positioning grid, company market share analysis, standards of measurement, top to bottom analysis and vendor share analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Primary Respondents

  • Demand Side: Manufacturers, Oncologists, Healthcare Industries, Scientists and Research Laboratories
  • Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence and Regulatory Affairs Managers among others.

Related Reports

Browse in Healthcare Category Related Reports@ https://www.databridgemarketresearch.com/report-category/healthcare/